India, Aug. 28 -- IMUNON, Inc. (IMNN), a clinical-stage biotechnology company, announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring uninterrupted trading on The Nasdaq Capital Market.
The confirmation came from the Nasdaq Hearings Panel.
President and CEO Stacy Lindborg said the restored compliance secures liquidity for investors and aligns with IMUNON's recent 15% stock dividend, highlighting confidence in its clinical pipeline.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
She noted that momentum follows strong Phase 2 results for IMNN-001, the company's DNA-based immunotherapy for advanced ovarian cancer, with a Phase 3 OVATION 3 trial now underway in North ...